Drug intelligence / Profile preview

megestrol acetate

Development stage: Approved
Lead developer: Advagen
Modality: Small Molecules
Administration: Oral

Overview

Megestrol acetate is a synthetic derivative of progesterone with potent progestational and anti-estrogenic properties. Marketed by Advagen under the brand name MEGVAL, it is primarily indicated for the palliative treatment of advanced breast and endometrial carcinomas, as well as for the management of anorexia, cachexia, or significant weight loss in patients with cancer or HIV/AIDS. The drug's appetite-stimulating effect is believed to be mediated through the hypothalamus and the modulation of inflammatory cytokines like IL-1, IL-6, and TNF-alpha. It is typically administered orally in tablet form.

Brand names: MEGVAL
Other names: megestrol acetatemegestrol17-alpha-acetoxy-6-dehydro-6-methylprogesterone

Targets

GR (Glucocorticoid receptor)PR (Progesterone receptor)AR (Adrenergic receptors)

Beyond the preview

Go deeper on megestrol acetate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on megestrol acetate.

Explore the full profile